Dysfunction of the CD38-Miro1 Axis Disrupts Astrocyte-neuron Mitochondrial Transfer in Alzheimer's Disease: Mechanisms and Therapeutic Restoration

This review article examines a newly appreciated rescue system in the brain where astrocytes — support cells surrounding neurons — can physically donate their own mitochondria to energy-starved neurons through microscopic tunnels called tunneling nanotubes (TNTs). The transfer is orchestrated by a molecular chain reaction: a neuronal distress signal activates CD38 on astrocytes, CD38 produces cyclic ADP-ribose, which triggers calcium release, and that calcium signal activates Miro1, a protein that physically moves mitochondria along cellular highways toward the astrocyte membrane for export. In Alzheimer's disease (AD), the authors argue this entire rescue pipeline fails simultaneously: NAD+ levels drop (starving CD38 of its fuel), amyloid-beta and tau proteins disrupt calcium handling and microtubule tracks respectively, and oxidative stress degrades the TNTs themselves. The result is a vicious cycle — neurons most in need of mitochondrial support are least able to receive it, accelerating the bioenergetic collapse that underlies synaptic loss and cognitive decline. The review is significant because it reframes AD pathology not just as a protein-aggregation problem but as a failure of intercellular metabolic cooperation. The authors survey emerging therapeutic strategies targeting each broken node: NAD+ precursors (like NMN or NR) to reactivate CD38, small molecules to stabilize Miro1 trafficking, and interventions to preserve TNT integrity. This mechanistic synthesis suggests that restoring the astrocyte-to-neuron mitochondrial shunt could represent a genuinely disease-modifying approach orthogonal to current amyloid- or tau-clearance strategies.

• The astrocyte-to-neuron mitochondrial transfer pathway is governed by a defined molecular cascade: neuronal distress → astrocytic CD38 activation → cyclic ADP-ribose (cADPR) production → intracellular Ca²⁺ release → Miro1-mediated peripheral repositioning of mitochondria via kinesin motors → TNT-mediated export to neurons.
• In AD, at least four converging pathological processes dismantle this cascade: (1) NAD+ depletion suppresses CD38 enzymatic activity; (2) Aβ-induced calcium dyshomeostasis causes sustained Ca²⁺ overload, which paradoxically stalls Miro1 and disengages kinesin motors; (3) tau hyperphosphorylation destabilizes microtubule tracks required for mitochondrial trafficking; and (4) oxidative stress physic
• Transient, localized Ca²⁺ signals physiologically promote mitochondrial docking at the plasma membrane for export, whereas pathologically sustained Ca²⁺ elevation switches Miro1 into a motor-disengaged state — a mechanistic dichotomy that explains how the same molecule can be both required for and inhibited by calcium signaling depending on signal dynamics.
• The review identifies three therapeutic restoration strategies with mechanistic rationale: NAD⁺ augmentation (via NMN/NR) to restore CD38 substrate availability; Miro1 stabilizers to rescue trafficking despite residual tau- or Aβ-mediated insults; and TNT-protective agents to maintain the structural conduits for organelle transfer.
• The authors frame AD bioenergetic failure as a 'multi-level vicious cycle': mitochondrial dysfunction in neurons increases distress signaling demand at the same time as the astrocytic rescue machinery is being destroyed, meaning the gap between supply and demand widens exponentially as disease progresses.

This is a narrative/systematic review article with no primary experimental data; no patient cohort or animal sample size applies. The authors synthesize published literature on CD38 biochemistry, Miro1 mitochondrial trafficking, TNT biology, and AD pathophysiology to construct a unified mechanistic model. The review is structured as a linear molecular cascade dissection followed by a parallel analysis of how each node is disrupted in AD, concluding with a therapeutic targeting framework. As a review, no pre-registration, blinding, or follow-up period is applicable.

Because this is a review with no original experimental data, the proposed CD38→cADPR→Ca²⁺→Miro1→TNT cascade as a unified in vivo pathway in human AD brain has not been directly validated end-to-end; each mechanistic link is inferred from studies conducted in different model systems (cell lines, rodents, isolated organelles). The relative quantitative contribution of this mitochondrial shunt failure to overall AD neurodegeneration versus amyloid/tau toxicity remains undefined. Critical next experiments would include: (1) in vivo real-time imaging of astrocyte-to-neuron mitochondrial transfer in AD mouse models at different disease stages; (2) conditional Miro1 rescue in astrocytes to test whether restoring trafficking is sufficient to ameliorate synaptic or cognitive deficits; and (3) human post-mortem or iPSC-derived co-culture studies directly quantifying transfer rates against CD38 and NAD+ levels across AD Braak stages.

This review extends [§41], which provides a comprehensive mechanistic and preclinical overview of mitochondrial transfer broadly, by drilling into the specific AD-relevant CD38-Miro1 signaling axis and its pathological failure — adding disease-context specificity that the broader transfer review lacks. It parallels [§99], which addresses how mitochondrial stress products drive inflammation and senescence during aging, since both articles identify mitochondrial dysfunction as a source of feed-forward pathological signaling rather than merely a downstream consequence; however, [§99] focuses on mtRNA-mediated innate immune activation while the current article focuses on intercellular organelle rescue failure. The article also parallels [§28], which demonstrates astrocyte/immune-cell mitochondrial transfer via extracellular vesicles in asthma, reinforcing the emerging consensus that intercellular mitochondrial donation is a conserved stress-response mechanism across tissue types and disease contexts. Thematically, it complements [§71], which documents mitochondrial dysfunction driving organ pathology in polycystic kidney disease — together these reviews support a cross-disease framework in which bioenergetic failure rooted in organelle dysfunction is a final common pathway amenable to organelle-targeted therapeutics.

• Mitochondrial transfer: A comprehensive analysis of mechanistic insights, preclinical applications, and technological innovations
  Directly covers the mechanistic and preclinical landscape of mitochondrial transfer across cell types; reading both reveals what is general to all intercellular transfer biology versus what is AD-specific in the CD38-Miro1 model.
• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Both articles address mitochondrial stress signaling in aging/neurodegeneration, but [id=99] focuses on mtRNA release driving inflammation during senescence — comparing them clarifies whether mitochondrial dysfunction is best targeted by blocking its inflammatory outputs or by restoring transfer-based rescue.
• Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma
  Demonstrates astrocyte-to-immune-cell mitochondrial transfer via extracellular vesicles in asthma, providing an important mechanistic parallel and contrast: EV-mediated versus TNT-mediated transfer routes, and whether the CD38-Miro1 axis operates similarly outside the CNS.
• The Role of Mitochondria in Polycystic Kidney Disease
  Documents mitochondrial dysfunction as a primary pathogenic driver in a non-neurological disease (PKD), allowing readers to assess how transferable the 'restore mitochondrial function to rescue organ pathology' therapeutic logic is across disease contexts.
• Transglutaminase and its role in Alzheimer's disease: focus on mitochondria, aging, defective mitophagy, synaptic degeneration, and metabolomics
  Focuses on transglutaminase-mediated mitochondrial dysfunction, mitophagy failure, and synaptic degeneration in AD — a mechanistically adjacent review that complements the CD38-Miro1 transfer narrative by covering the quality-control side of the same mitochondrial crisis in AD neurons.